Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells

PLoS Computational Biology

Volumn 7, Issue 3, 2011, Pages

  Cavill, Rachel ^a   Kamburov, Atanas ^b   Ellis, James K ^a   Athersuch, Toby J ^a   Blagrove, Marcus S C ^c   Herwig, Ralf ^b   Ebbels, Timothy M D ^a   Keun, Hector C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMOTHERAPY; DATA INTEGRATION; INTEGRATION; PHYSIOLOGY; PLATINUM; TUMORS;

BIOCHEMICAL PATHWAY; CELL LINES; CHEMOSENSITIVITY; DIRECT INTEGRATION; METABOLIC PATHWAYS; METABOLOMICS; METABOLOMICS DATA; PROFILE DATA; TRANSCRIPTOMICS; TUMOUR CELLS;

METABOLISM;

ARTICLE; CELL METABOLISM; CHEMOSENSITIVITY; EXCISION REPAIR; GROWTH INHIBITION; METABOLOMICS; NUCLEOTIDE METABOLISM; PHENOTYPE; PROTEIN TRANSPORT; PURINE METABOLISM; TRANSCRIPTOMICS; TUMOR CELL; BIOLOGY; CHEMISTRY; DNA MICROARRAY; DRUG SCREENING; GENETIC TRANSCRIPTION; HUMAN; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; IPROPLATIN; LIPOPROTEIN; PLATINUM COMPLEX; TETRAPLATIN;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; COMPUTATIONAL BIOLOGY; DRUG SCREENING ASSAYS, ANTITUMOR; FALSE POSITIVE REACTIONS; HUMANS; LIPOPROTEINS; METABOLOMICS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PHENOTYPE; TRANSCRIPTION, GENETIC;

EID: 79953663708     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1001113     Document Type: Article

References (55)

1. Ebbels TMD, Cavill R, (2009) Bioinformatic methods in NMR-based metabolic profiling. Prog Nucl Mag Res Sp 55: 361-374.
2. Craig A, Sidaway J, Holmes E, Orton T, Jackson D, et al. (2006) Systems Toxicology: Integrated Genomic, Proteomic and Metabonomic Analysis of Methapyrilene Induced Hepatotoxicity in the Rat. J Proteome Res 5: 1586-1601.
3. Hirai MY, Yano M, Goodenowe DB, Kanaya S, Kimura T, et al. (2004) Integration of transcriptomics and metabolomics for understanding of global responses to nutritional stresses in Arabidopsis thaliana. Proc Natl Acad Sci USA 101: 10205-10210.
4. Heijne WHM, Stierum RH, Slijper M, van Bladeren PJ, van Ommen B, (2003) Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. Biochem Pharmacol 65: 857-875.
5. Lanckriet GR, De Bie T, Cristianini N, Jordan MI, Noble WS, (2004) A statistical framework for genomic data fusion. Bioinformatics 20: 2626-2635.
6. Rantalainen M, Cloarec O, Beckonert O, Wilson ID, Jackson D, et al. (2006) Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J Proteome Res 5: 2642-2655.
7. Joyce AR, Palsson BO, (2006) The model organism as a system: integrating 'omics' data sets. Nat Rev Mol Cell Biol 7: 198-210.
8. Bylesjo M, Eriksson D, Kusano M, Moritz T, Trygg J, (2007) Data integration in plant biology: the O2PLS method for combined modeling of transcript and metabolite data. Plant J 52: 1181-1191.
9. Dumas ME, Wilder SP, Bihoreau MT, Barton RH, Fearnside JF, et al. (2007) Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet 39: 666-672.
10. Chuang H-Y, Lee E, Liu Y-T, Lee D, Ideker T, (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140.
11. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM, (1999) Systematic determination of genetic network architecture. Nat Genet 22: 281-285.
12. Curtis RK, Oresic M, Vidal-Puig A, (2005) Pathways to the analysis of microarray data. Trends Biotechnol 23: 429-435.
13. Xia J, Wishart DS, (2010) MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucl Acids Res 38: W71-77.
14. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia. Circulation 112: 3868-3875.
15. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
16. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5: 853-867.
17. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832.
18. Holbeck S, (2007) Molecular Target Data. Available:http://dtp.nci.nih.gov/mtargets/download.html.
19. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 57: 289-300.
20. Kamburov A, Wierling C, Lehrach H, Herwig R, (2009) ConsensusPathDB-a database for integrating human functional interaction networks. Nucl Acids Res 37: D623-628.
21. Kanehisa M, Goto S, (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucl Acids Res 28: 27-30.
22. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, et al. (2005) Reactome: a knowledgebase of biological pathways. Nucl Acids Res 33: D428-432.
23. Romero P, Wagg J, Green M, Kaiser D, Krummenacker M, et al. (2004) Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 6: R2.
24. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, et al. (2009) PID: the Pathway Interaction Database. Nucl Acids Res 37: D674-679.
25. Hande KR, (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521.
26. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev 56: 185-229.
27. Hsu PP, Sabatini DM, (2008) Cancer Cell Metabolism: Warburg and Beyond. Cell 134: 703-707.
28. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E, (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin in Cancer Biol 15: 300-308.
29. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. (2007) Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350.
30. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR, (2007) 2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells. Cancer Res 67: 3364-3370.
31. Kartalou M, Essigmann JM, (2001) Mechanisms of resistance to cisplatin. Mutat Res-Fund Mol M 478: 23-43.
32. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
33. Wernyj RP, Morin PJ, (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Update 7: 227-232.
34. Preston TJ, Henderson JT, McCallum GP, Wells PG, (2009) Base excision repair of reactive oxygen species' initiated 7,8-dihydro-8-oxo-2-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther 8: 2015-2026.
35. Goodisman J, Hagrman D, Tacka K, Souid A-K, (2006) Analysis of cytotoxicities of platinum compounds. Cancer Chemoth Pharm 57: 257-267.
36. Koehler SE, Ladner RD, (2004) Small Interfering RNA-Mediated Suppression of dUTPase Sensitizes Cancer Cell Lines to Thymidylate Synthase Inhibition. Mol Pharmacol 66: 620-626.
37. Kowalski D, Pendyala L, Daignan-Fornier B, Howell SB, Huang R-Y, (2008) Dysregulation of Purine Nucleotide Biosynthesis Pathways Modulates Cisplatin Cytotoxicity in Saccharomyces cerevisiae. Mol Pharmacol 74: 1092-1100.
38. Tatidis L, Masquelier M, Vitols S, (2002) Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem Pharmacol 63: 2169-2180.
39. Shah T, Flonne W, Marie-France P, Paul TW Jr, Kristine G, et al. (2010) Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed 23: 633-642.
40. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, et al. (2008) A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 7: 3141-3149.
41. Heijne WHM, Lamers R-JAN, van Bladeren PJ, Groten JP, van Nesselrooij JHJ, et al. (2005) Profiles of Metabolites and Gene Expression in Rats with Chemically Induced Hepatic Necrosis. Toxicol Pathol 33: 425-433.
42. Rantalainen M, Cloarec O, Beckonert O, Wilson ID, Jackson D, et al. (2006) Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice. J Proteome Res 5: 2642-2655.
43. Hirai MY, Klein M, Fujikawa Y, Yano M, Goodenowe DB, et al. (2005) Elucidation of gene-to-gene and metabolite-to-gene networks in arabidopsis by integration of metabolomics and transcriptomics. J Biol Chem 280: 25590-25595.
44. Bradley PH, Brauer MJ, Rabinowitz JD, Troyanskaya OG, (2009) Coordinated concentration changes of transcripts and metabolites in Saccharomyces cerevisiae. PLoS Comp Bio 5: e1000270.
45. Gibon Y, Usadel B, Blaesing O, Kamlage B, Hoehne M, et al. (2006) Integration of metabolite with transcript and enzyme activity profiling during diurnal cycles in Arabidopsis rosettes. Genome Biol 7: R76.
46. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene Ontology: tool for the unification of biology. Nat Genet 25: 25-29.
47. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, et al. (2009) Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy. Cancer Res 69: 8302-8309.
48. Clayton AT, Lindon JC, Cloarec O, Antti H, Charuel C, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
49. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK, (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106: 14728-14733.
50. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, et al. (2010) Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans. Clin Pharmacol Ther 88: 45-51.
51. Keun HC, Sidhu J, Pchejetski D, Lewis JS, Marconell H, et al. (2009) Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy. Clin Cancer Res 15: 6716-6723.
52. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
53. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the Universal Protein knowledgebase. Nucl Acids Res 32: D115-119.
54. Degtyarenko K, Matos Pd, Ennis M, Hastings J, Zbinden M, et al. (2007) ChEBI: a database and ontology for chemical entities of biological interest. Nucl Acids Res 36: D344-50.
55. Oliveros JC, (2007) VENNY. An interactive tool for comparing lists with Venn Diagrams. Available:http://bioinfogp.cnb.csic.es/tools/venny/index.html.